[ad_1]
Menlo Park and Boston, California, December 10, 2021 (Global News Service)–Adicet Bio, Inc. (“Adicet”) (NASDAQ:acetic acid), a biotechnology company that discovers and develops allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the end of its previously announced underwriting public offering of 7,187,500 common shares, including all of its underwriters right. The option to purchase up to 937,500 shares of common stock at a public offering price of $14.00 per share, minus underwriting discounts and commissions. Before deducting underwriting discounts and commissions and issuance costs, the total proceeds of the offering were approximately US$100.6 million. All shares in this issuance will be sold by Adicet.
Jeffries and Guggenheim…
The full story can be found on Benzinga.com
[ad_2]
Source link
